GlassScriptPhysician profile
Lillian Bergeron
NPI 1245719731
$6,027.76
in general payments reported to CMS, 2019-2025
29 companies · $1,520 in 2025
The $1,520 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $396 · 2021: $580 · 2022: $863 · 2023: $1,055 · 2024: $1,119 · 2025: $1,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,535 · Entertainment: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,534.80 |
| Entertainment | $158.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $778.83 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $620.92 | 2019-2025 | Rocklatan, Hydrus Microstent, Precision 1 |
| Glaukos Corporation | $469.06 | 2024 | Idose, Istent Trabecular Micro-Bypass System Model Is3, Ce-Marked Kxla System |
| Allergan, INC. | $402.59 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $357.30 | 2019-2022 | |
| Optos, INC. | $357.11 | 2020-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Dompe US, INC. | $300.80 | 2023-2025 | Oxervate |
| Biotissue Holdings INC. | $299.27 | 2023-2025 | |
| Carl Zeiss Meditec USA, INC. | $279.39 | 2023 | Cirrus Hd-Oct, Clarus |
| Tarsus Pharmaceuticals, INC. | $270.95 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $251.46 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $219.57 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Abbvie INC. | $158.84 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $151.94 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $142.81 | 2022-2025 | Miebo, Xiidra, Vyzulta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $132.59 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2022 | |
| Coopervision INC. | $117.77 | 2024 | Clariti Contact Lens |
| Horizon Therapeutics Plc | $116.12 | 2022 | |
| Sun Pharmaceutical Industries INC. | $105.82 | 2019-2023 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $96.28 | 2019-2020 | |
| Astellas Pharma US INC | $82.63 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $42.60 | 2023-2024 | Tecnis Iol, Catalys System |
| Rxsight INC | $34.98 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Ocular Therapeutix, INC. | $28.84 | 2023 | Dextenza |
| Amgen INC. | $24.36 | 2024 | Tepezza |
| Mallinckrodt Hospital Products INC. | $24.33 | 2023 | Acthar |
| Mallinckrodt Enterprises LLC | $21.82 | 2019 | |
| Ivantis, INC | $13.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lillian Bergeron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.